Previous Close | 5.60 |
Open | 5.57 |
Bid | 6.10 x 400 |
Ask | 6.18 x 100 |
Day's Range | 5.52 - 6.15 |
52 Week Range | 1.28 - 16.24 |
Volume | |
Avg. Volume | 856,418 |
Market Cap | 431.966M |
Beta (5Y Monthly) | 0.88 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Senior R&D leader brings extensive expertise in immunology, clinical development and translational scienceSOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies today announced that translational immunology expert George Vratsanos, M.D., FACR, is joining its board of directors. Dr. Vratsanos currently serves as Chief Medical Officer and Head of R&D for Jnana Th
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investmentsStrong balance sheet, bolstered by recent $240.1 million offering, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural kil
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences: Needham Virtual Healthcare ConferenceApril 9, 20241:30 p.m. ET – fireside chat Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 15, 20241:00 p.m. ET – panel discussion A simultaneous webcast of each event will be available on the Inves